Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
19 results
D1.372 - Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria
D1.375 - Ciclosporin for omalizumab-refractory CSU in a Paediatric population in Cork University Hospital: a case series
D1.376 - Emerging inmunomodulatory agents for atopic dermatitis
D1.377 - Berotralstat effectively controls a type 2 Hereditary Angioedema patient, refractory to other long-term prophylaxis treatments – Case report
D1.378 - Evaluating the efficacy of dupilumab treatment for atopic dermatitis across geographic areas: A systematic review and meta-regression analysis
D1.379 - AllergoOncology: Generation of Equinized Anti-PD-L1 mAbs with Specific Equine Constant Regions by MOE-PCR Ligation-Independent Cloning (LIC)
D1.380 - Quicker EASI 75 or greater decline of DLQI - is it significant? Comparison of dupilumab treatment among children and adults in two centres in Cracow
D1.383 - Nonimmediate hypersensitivity reaction to Lanadelumab in a patient with Hereditary Angioedema: a case report
D1.384 - Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis
D1.385 - Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity
D1.386 - Impact of dupilumab on allergen specific immunoglobulin E production
- D1.323 - Clinical Experience with Lanadelumab for Hereditary Angioedema in Kazakhstan
D3.317 - Moderate-to-severe infections and initial SELENA-SLEDAI correlate with the incidence of flares in patients with Systemic Lupus Erythematosus
D3.322 - Acquired chronic granulomatous disease secondary to myelodysplastic disorder
D3.324 - Mastoiditis as complication of Hyper IgM syndrome
D3.326 - A RARE COEXISTENCE: CARD9 DEFICIENCY AND IgG4-RELATED DISEASE IN A PEDIATRIC PATIENT
D3.327 - Use of C1 Inhibitor Subcutaneously in the United Kingdom
D3.328 - Relapsing COVID-19 pneumonia and Helicobacter cineadi cellulitis in a patient with X-linked agammaglobulinemia
D3.332 - Determination of Reference Intervals for IgG, IgA, and IgM Levels by Age in Healthy Adults
Download the app
The congress at your fingertips
Available on
Download